Sanofi SA vs Clear Secure Inc — how do they compare? Sanofi SA trades at $43.62 (market cap $104.30B), while Clear Secure Inc trades at $46.8 (market cap $4.98B). The key difference: Sanofi SA is far larger — about 20.9× Clear Secure Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | YOU | |
|---|---|---|
Market Cap | $104.30B | $4.98B |
Sector | Health | Technology |
52-Week High | $52.34 | $62.36 |
52-Week Low | $41.33 | $29.61 |
Enterprise Value | $124.19B | $4.13B |
Dividend Yield | 5.55% | 1.19% |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
CLEAR Secure (YOU) trades at $46.98, down 8.26% in 24 hours, reflecting recent bearish pressure but holding above key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.49 per share, revenue growth to $1.0 billion in 2026, and robust profitability margins. Technical indicators are mixed, with moving averages bearish but oscillators like RSI suggesting potential oversold conditions. Recent news highlights expansion in identity verification services and corporate memberships.
Outlook is cautiously optimistic due to earnings beats and growth initiatives, but risks include high valuation multiples and market volatility. Analysts are divided with a near-even buy/hold split, indicating balanced sentiment. Investors should weigh strong operational cash flow against competitive pressures in the identity security sector.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →